THEMISMED vs ZIMLAB: Stock Comparison

Themis Medicare Limited vs Zim Laboratories Limited

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

Themis Medicare Limited is the larger company by market capitalisation. Themis Medicare Limited shows a higher dividend yield and faster revenue growth, while Zim Laboratories Limited shows a lower P/E, a higher ROE and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Themis Medicare Limited and Zim Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, THEMISMED is more favourable on 5 of 13 scored metrics and ZIMLAB on 8These counts are context-free and are not an overall rating.

Key Differences

Market Cap
THEMISMED is the larger company
₹972 Cr vs ₹617 Cr
P/E Ratio
ZIMLAB has a lower P/E
105.73x vs 883.33x
P/B Ratio
ZIMLAB has a lower P/B
2.08x vs 2.45x
EPS
ZIMLAB has higher earnings per share
₹1.94 vs ₹0.12
Dividend Yield
THEMISMED has a higher dividend yield
0.43% vs 0.02%
Revenue Growth (TTM YoY)
THEMISMED has faster revenue growth
6.7% vs -3.36%
EPS Growth (TTM YoY)
THEMISMED has faster EPS growth
0% vs -47.01%
Qtr Sales Growth
THEMISMED has stronger quarterly sales growth
6.74% vs -12.3%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricTHEMISMEDZIMLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricTHEMISMEDZIMLAB
Live Price₹105.78₹104.91
Day Change-1.99%0.25%
Volume34,27181,241
52-Week High₹148₹115.17
52-Week Low₹64.95₹59.31
Distance from 52W High-28.53%-8.91%

Valuation

MetricTHEMISMEDZIMLAB
Market Cap₹972 Cr₹617 Cr
P/E Ratio883.33x105.73x
P/B Ratio2.45x2.08x
EPS₹0.12₹1.94
Book Value₹43.06₹51.77
Dividend Yield0.43%0.02%

Growth

MetricTHEMISMEDZIMLAB
Revenue Growth (TTM YoY)6.7%-3.36%
EPS Growth (TTM YoY)0%-47.01%
Qtr Sales Growth6.74%-12.3%
Qtr Profit Growth192%-308%

Profitability & Leverage

MetricTHEMISMEDZIMLAB
ROE0.29%1.97%
ROCE2.74%8.16%
Net Margin0.33%1.56%
Operating Margin-2.9%5.72%
Debt to Equity25.11x0.42x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricTHEMISMEDZIMLAB
Promoter Holding57.5%30.36% 0.01 pp
FII Holding0.01% 0.1 pp0.03% 0.03 pp
DII Holding0.01%1.33% 1.26 pp
Public Holding32.87% 0.09 pp68.28% 1.3 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Themis Medicare Limited and Zim Laboratories Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.